Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?

被引：0
|
作者：
Choi, Jonggi [1 ]
Choi, Won-Mook [1 ]
Lim, Young-Suk [1 ]
机构：
[1] Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, 88, Olymp Ro 43-gil, Seoul 05505, South Korea
来源：
CLINICS IN LIVER DISEASE | 2023年 / 27卷 / 04期
关键词：
Lamivudine; Adefovir; Entecavir; Tenofovir; Hepatitis B; Hepatocellular carcinoma; CHRONIC HEPATITIS-B; TENOFOVIR DISOPROXIL FUMARATE; HEPATOCELLULAR-CARCINOMA; DOUBLE-BLIND; ANTIVIRAL THERAPY; VIRUS INFECTION; ENTECAVIR; ALAFENAMIDE; RESISTANCE; PHASE-3;
D O I：
10.1016/j.cld.2023.05.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：809 / 818
页数：10
相关论文
共 50 条
  • [1] Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs
    Petersen, Joerg
    Buti, Maria
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 6 (06) : 683 - 694
  • [2] Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
    Siakavellas, Spyros
    Goulis, John
    Manolakopoulos, Spilios
    Triantos, Christos
    Gatselis, Nikolaos
    Tsentemidou, Eva
    Kranidioti, Hariklia
    Zisimopoulos, Konstantinos
    Tsoulas, Christos
    Dalekos, George
    Papatheodoridis, George
    ANNALS OF GASTROENTEROLOGY, 2021, 34 (01): : 73 - 79
  • [3] Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?
    Ayoub W.S.
    Martin P.
    Lampertico P.
    Current Hepatology Reports, 2015, 14 (4) : 279 - 283
  • [4] Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs
    Yamashige, Daiki
    Hosaka, Tetsuya
    Suzuki, Fumitaka
    Fujiyama, Shunichiro
    Kawamura, Yusuke
    Sezaki, Hitomi
    Akuta, Norio
    Kobayashi, Masahiro
    Suzuki, Yoshiyuki
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Kobayashi, Mariko
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2021, 56 (11) : 1008 - 1021
  • [5] Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?
    Petersen, Jorg
    JOURNAL OF HEPATOLOGY, 2015, 62 (03) : 505 - 507
  • [6] Consequences of persistent HBV infection in HIV: the double-edged sword of nucleos(t)ide analogs
    Boyd, Anders
    Girard, Pierre-Marie
    Lacombe, Karine
    FUTURE VIROLOGY, 2012, 7 (02) : 139 - 148
  • [7] Lack of Pharmacokinetic Drug-Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs
    Han, Kelong
    Youssef, Amir S.
    Magee, Mindy
    Hood, Steve
    Tracey, Helen
    Kwoh, Jesse
    Theodore, Dickens
    Paff, Melanie
    Nader, Ahmed
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025, 14 (04): : 281 - 291
  • [8] Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
    Moreno-Cubero, Elia
    Sanchez del Arco, Robert T.
    Pena-Asensio, Julia
    Sanz de Villalobos, Eduardo
    Miquel, Joaquin
    Ramon Larrubia, Juan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (17) : 1825 - 1838
  • [9] The relationship between the use of nucleos(t)ide analogs and metabolic parameters in patients with chronic hepatitis B
    Yakut, A.
    Aladag, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (19) : 9315 - 9323
  • [10] HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs?
    Buti, Maria
    LIVER INTERNATIONAL, 2014, 34 : 108 - 111
12345